ALNY
Price
$449.58
Change
-$8.79 (-1.92%)
Updated
Sep 25 closing price
Capitalization
58.93B
27 days until earnings call
AXSM
Price
$116.50
Change
+$0.49 (+0.42%)
Updated
Sep 26, 11:38 AM (EDT)
Capitalization
5.79B
45 days until earnings call
Interact to see
Advertisement

ALNY vs AXSM

Header iconALNY vs AXSM Comparison
Open Charts ALNY vs AXSMBanner chart's image
Alnylam Pharmaceuticals
Price$449.58
Change-$8.79 (-1.92%)
Volume$685.31K
Capitalization58.93B
Axsome Therapeutics
Price$116.50
Change+$0.49 (+0.42%)
Volume$295
Capitalization5.79B
ALNY vs AXSM Comparison Chart in %
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. AXSM commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Buy and AXSM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (ALNY: $449.58 vs. AXSM: $116.01)
Brand notoriety: ALNY and AXSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 57% vs. AXSM: 72%
Market capitalization -- ALNY: $58.93B vs. AXSM: $5.79B
ALNY [@Biotechnology] is valued at $58.93B. AXSM’s [@Biotechnology] market capitalization is $5.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileAXSM’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • AXSM’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than AXSM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 3 TA indicator(s) are bullish while AXSM’s TA Score has 4 bullish TA indicator(s).

  • ALNY’s TA Score: 3 bullish, 5 bearish.
  • AXSM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AXSM is a better buy in the short-term than ALNY.

Price Growth

ALNY (@Biotechnology) experienced а -0.57% price change this week, while AXSM (@Biotechnology) price change was -2.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.01%. For the same industry, the average monthly price growth was +9.06%, and the average quarterly price growth was +48.80%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

AXSM is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($58.9B) has a higher market cap than AXSM($5.79B). ALNY YTD gains are higher at: 91.059 vs. AXSM (37.111). ALNY has higher annual earnings (EBITDA): -170.84M vs. AXSM (-230.81M). ALNY has more cash in the bank: 2.86B vs. AXSM (303M). AXSM has less debt than ALNY: AXSM (217M) vs ALNY (1.3B). ALNY has higher revenues than AXSM: ALNY (2.46B) vs AXSM (495M).
ALNYAXSMALNY / AXSM
Capitalization58.9B5.79B1,017%
EBITDA-170.84M-230.81M74%
Gain YTD91.05937.111245%
P/E RatioN/AN/A-
Revenue2.46B495M497%
Total Cash2.86B303M943%
Total Debt1.3B217M598%
FUNDAMENTALS RATINGS
ALNY vs AXSM: Fundamental Ratings
ALNY
AXSM
OUTLOOK RATING
1..100
7977
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
861
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3949
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXSM's Valuation (89) in the Pharmaceuticals Other industry is in the same range as ALNY (96) in the Biotechnology industry. This means that AXSM’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (8) in the Biotechnology industry is somewhat better than the same rating for AXSM (61) in the Pharmaceuticals Other industry. This means that ALNY’s stock grew somewhat faster than AXSM’s over the last 12 months.

ALNY's SMR Rating (100) in the Biotechnology industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that ALNY’s stock grew similarly to AXSM’s over the last 12 months.

ALNY's Price Growth Rating (39) in the Biotechnology industry is in the same range as AXSM (49) in the Pharmaceuticals Other industry. This means that ALNY’s stock grew similarly to AXSM’s over the last 12 months.

ALNY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that ALNY’s stock grew similarly to AXSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYAXSM
RSI
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
72%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
64%
Bearish Trend 11 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSCNX18.13N/A
N/A
Penn Capital Special Sits Sm Cp Eq Inst
FTVFX36.19N/A
N/A
Fidelity Advisor Value M
TRBIX26.38N/A
N/A
Nuveen Small Cap Blend Idx Retire
VSVIX32.20N/A
N/A
Victory Integrity Small-Cap Value Y
SMCWX74.30-0.77
-1.03%
American Funds SMALLCAP World A